​

Fate Therapeutics (FATE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

FATE Stock Forecast

Fate Therapeutics (FATE) stock forecast, based on 27 Wall Street analysts, predicts a 12-month average price target of $4.00, with a high of $5.00 and a low of $3.00. This represents a 260.36% increase from the last price of $1.11.

$1 $2 $3 $4 $5 $6 $7 $8 High: $5 Avg: $4 Low: $3 Last Closed Price: $1.11

FATE Stock Rating

Fate Therapeutics stock's rating consensus is Buy, based on 27 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (51.85%), 12 Hold (44.44%), 1 Sell (3.70%), and 0 Strong Sell (0.00%).

Buy
Total 27 1 12 14 Strong Sell Sell Hold Buy Strong Buy

FATE Price Target Upside V Benchmarks

TypeNameUpside
StockFate Therapeutics260.36%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts-18
Avg Price Target-$3.00$5.38
Last Closing Price$1.11$1.11$1.11
Upside/Downside-170.27%384.68%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 252311--16
Mar, 252312--17
Feb, 252412--18
Jan, 252412--18
Dec, 242412--18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 06, 2025Stifel Nicolaus$3.00$1.04188.46%170.27%
Nov 13, 2024Etzer DaroutBMO Capital$5.00$3.3748.37%350.45%
Aug 14, 2024Benjamin BurnettStifel Nicolaus$5.00$3.2752.91%350.45%
Jun 17, 2024Edward TenthoffPiper Sandler$6.00$3.6166.20%440.54%
May 16, 2024Debjit ChattopadhyayH.C. Wainwright$5.00$4.2417.92%350.45%
May 10, 2024Edward TenthoffPiper Sandler$4.00$3.883.09%260.36%
May 10, 2024Etzer DaroutBMO Capital$6.00$3.8755.04%440.54%
May 10, 2024Bill MaughanCanaccord Genuity$9.00$3.90130.77%710.81%
Jan 09, 2023Goldman Sachs$4.00$4.40-9.09%260.36%
Jan 06, 2023Morgan Stanley$8.00$4.2289.57%620.72%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 18, 2024OppenheimerPerformPerformhold
Nov 13, 2024BMO CapitalMarket PerformMarket Performhold
Aug 14, 2024Cowen & Co.HoldHoldhold
Aug 14, 2024BMO CapitalMarket PerformMarket Performhold
Aug 14, 2024Piper SandlerOverweightOverweighthold
Jun 17, 2024Sandler O'NeillUnderperformUnderperformhold
Jun 17, 2024Piper SandlerNeutralOverweightupgrade
May 16, 2024H.C. WainwrightNeutralNeutralhold
May 10, 2024Piper SandlerNeutralNeutralhold
May 10, 2024BMO CapitalMarket PerformMarket Performhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.07$-2.18$-2.63$-1.64$-1.64----
Avg Forecast$-1.83$-2.21$-3.21$-1.72$-1.63$-1.67$-1.50$-1.33$-1.30
High Forecast$-1.44$-1.73$-2.66$-1.63$-1.18$-0.81$-1.16$-0.84$-1.11
Low Forecast$-2.82$-3.40$-4.84$-1.89$-1.90$-2.08$-2.18$-2.07$-1.48
Surprise %13.11%-1.36%-18.07%-4.65%0.61%----

Revenue Forecast

$0 $20M $40M $60M $80M $100M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$31.43M$55.85M$96.30M$63.53M$13.63M----
Avg Forecast$20.58M$50.85M$69.09M$63.40M$13.52M$3.67M$4.14M$14.05M$55.63M
High Forecast$29.14M$72.00M$96.14M$63.88M$16.05M$4.08M$4.23M$15.61M$61.81M
Low Forecast$17.15M$42.38M$59.97M$62.73M$12.59M$3.26M$4.05M$12.49M$49.44M
Surprise %52.74%9.82%39.38%0.22%0.82%----

Net Income Forecast

$-350M $-290M $-230M $-170M $-110M $-50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-170.30M$-206.30M$-255.06M$-160.93M$-186.26M----
Avg Forecast$-128.58M$-196.17M$-277.96M$-160.93M$-178.23M$-142.14M$-164.13M$-143.33M$-127.55M
High Forecast$-102.87M$-156.94M$-222.37M$-128.74M$-116.39M$-79.24M$-113.96M$-82.51M$-109.13M
Low Forecast$-154.30M$-235.41M$-333.55M$-193.11M$-187.41M$-205.04M$-214.29M$-204.15M$-145.97M
Surprise %32.44%5.16%-8.24%-4.51%----

FATE Forecast FAQ

Is Fate Therapeutics stock a buy?

Fate Therapeutics stock has a consensus rating of Buy, based on 27 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 12 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Fate Therapeutics is a favorable investment for most analysts.

What is Fate Therapeutics's price target?

Fate Therapeutics's price target, set by 27 Wall Street analysts, averages $4 over the next 12 months. The price target range spans from $3 at the low end to $5 at the high end, suggesting a potential 260.36% change from the previous closing price of $1.11.

How does Fate Therapeutics stock forecast compare to its benchmarks?

Fate Therapeutics's stock forecast shows a 260.36% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Fate Therapeutics over the past three months?

  • April 2025: 12.50% Strong Buy, 18.75% Buy, 68.75% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 11.76% Strong Buy, 17.65% Buy, 70.59% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 11.11% Strong Buy, 22.22% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.

What is Fate Therapeutics’s EPS forecast?

Fate Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.67, marking a 1.83% increase from the reported $-1.64 in 2024. Estimates for the following years are $-1.5 in 2026, $-1.33 in 2027, and $-1.3 in 2028.

What is Fate Therapeutics’s revenue forecast?

Fate Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $3.67M, reflecting a -73.05% decrease from the reported $13.63M in 2024. The forecast for 2026 is $4.14M, followed by $14.05M for 2027, and $55.62M for 2028.

What is Fate Therapeutics’s net income forecast?

Fate Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-142M, representing a -23.69% decrease from the reported $-186M in 2024. Projections indicate $-164M in 2026, $-143M in 2027, and $-128M in 2028.